Rubik Therapeutics is on a mission to change the treatment paradigm for solid tumors by developing cell therapies that target highly selective, unique tumor targets and by leveraging insights into immune cells signaling to counteract immune suppression.
Driven to discover first-in-class cell therapies for solid cancers.
Rubik Therapeutics is an early-stage biotech pioneering next-generation solid cancer targets and pan-checkpoint immune suppression control for both autologous or allogeneic solid tumor cell therapies.
Our mission is to unlock the potential of safer, efficacious cell therapies in solid cancer indications with high unmet need.
Rubik also leverages its platform capabilities to identify selective targets for other modalities in adjacent spaces outside of cell therapy. We are also seeking partnerships for our immune checkpoint modulator platform with other cell therapy companies. Please reach out to us.
Rubik’s proprietary platform is built on foundational technology that codes our discoveries in cancer and immune gene regulation into a comprehensive discovery engine.
“In solid tumors there is no such thing as a selective target due to the sharing of antigens between tumors and essential tissues” -Ray Fladeboe
Through computational and statistical modeling of cancer genomes, Rubik discovered a defined set of properties that can be coded to discover truly selective solid tumor targets. These properties stem from the propensity for cancer genomes to select for various genetic lesions during cancer initiation and progression which can also affect other, non-cancer associated genes. During tumorigenesis, chromosome-adjacent genes or even non-proximal associated genes become ‘linked’ to cancer-driving lesions and become dysregulated. We refer to these properties as onco-linkage.
Onco-linked targets exhibit several features that make them attractive tumor-selective targets:
We have also discovered a set of targets relevant for non-cell therapy target-dependent modalities such as radioligand therapies that we are actively partnering. Please reach out to us to learn more.
Feel free to drop us a line and we will get back to you as soon as possible.